What the research examined
Observational studies have examined GLP-1 medicines in people with inflammatory bowel disease. A retrospective semaglutide study reported weight-related outcomes and selected disease events. A separate target-trial emulation examined whether adding semaglutide or tirzepatide was associated with improved outcomes in stable inflammatory bowel disease; it did not demonstrate that proposed benefit.
How to interpret the findings
These analyses use clinical records rather than randomized assignment. Treatment selection, incomplete records, and discontinuation can influence comparisons. Findings about weight or selected adverse events should not be recast as evidence that a medicine treats inflammatory bowel disease.
Research literature
- Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity.
Inflammatory bowel diseases · 2025 · PMID 38642103 - Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · PMID 42309434
Links open the indexed paper records. Summaries are based on those records and their available abstracts, not a systematic review or a full-text appraisal of every study.